RGLS
Regulus Therapeutics Inc.
Set alert
8.16 0.00 0.00%
8.16 Day range 8.16
52-week range unavailable
- YTD
- +416.46%
- 1 year
- +298.05%
- Open
- 8.16
- Prev close
- 8.16
- Mkt cap
- 100.22M
- Vol
- 8.76M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.16
- High
- 8.16
- Forward P/E
- -1.26
- Beta
- 1.63
- Short ratio
- 3.38
- Inst. own
- 88.26%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.53
- 200-d avg
- 1.89
- 1y target
- 10.33
Key statistics
- Market cap
- 100.22M
- Enterprise value
- 18.08M
- Trailing P/E
- 0.00
- Forward P/E
- -1.26
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.15
- EPS (TTM)
- -1.02
- Beta
- 1.63
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -21.58M
- Total cash
- 87.31M
- Total debt
- 1.24M
- Return on equity
- -72.36%
- Shares outstanding
- 65.50M
- Short % of float
- 2.72%
- 50-day average
- 1.53
- 200-day average
- 1.89
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 10.33 +26.6% upside
Now 8.16
- Target (low)
- 3.00
- Target (mean)
- 10.33
- Target (high)
- 28.00
Ratings (0m) 6 5 buy · 1 hold · 0 sell
- Strong buy1
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.23.
Financials — quick view
RGLS Revenue — quarterly 0
RGLS Net income — quarterly -9.63M
RGLS EPS — quarterly -0.15
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.18 | -0.21 | -0.03 | -16.67% |
| Aug 8, 2024 | Jun 1, 2024 | -0.17 | -0.17 | 0.00 | 0.00% |
| May 9, 2024 | Mar 1, 2024 | -0.15 | -0.29 | -0.14 | -93.33% |
| Mar 21, 2024 | Dec 1, 2023 | -0.40 | -0.40 | 0.00 | 0.00% |
| Nov 9, 2023 | Sep 1, 2023 | -0.36 | -0.40 | -0.04 | -11.11% |
| Aug 8, 2023 | Jun 1, 2023 | -0.39 | -0.37 | +0.02 | +5.13% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 30, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Aug 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 25, 2024 | Canaccord Genuity | main | Buy | Buy |
About Regulus Therapeutics Inc.
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- regulusrx.com
News
- Novartis AGcompleted the acquisition of Regulus Therapeutics Inc..
- Novartis completes acquisition of Regulus Therapeutics
- Novartis announces commencement of tender offer to acquire Regulus Therapeutics
- Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates
- REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS
- SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS
- Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher
- Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
- RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders
- Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders
Your note
Sign in to keep a note on RGLS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AKER CHRISTOPHER RAY | General Counsel | Sale | Jan 17, 2024 | 10,056 |
| CALSADA CRISPINA CPA | Chief Financial Officer | Sale | Jan 17, 2024 | 5,782 |
| COLLIER KATHRYN J. | Director | Purchase | Jul 24, 2024 | 6,740 |
| HAGAN JOSEPH PATRICK | Chief Executive Officer | Sale | Jan 17, 2024 | 57,112 |
| PAPADOPOULOS STELIOS B | Director | Stock Award(Grant) | Mar 13, 2024 | 978,388 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes, Inc. | 19.62% | 12,852,654 | 19.66M | Sep 29, 2024 |
| NEA Management Company, LLC | 9.87% | 6,467,802 | 9.90M | Sep 29, 2024 |
| Vivo Capital, LLC | 7.63% | 5,000,000 | 7.65M | Sep 29, 2024 |
| Octagon Capital Advisors LP | 6.51% | 4,263,701 | 6.52M | Sep 29, 2024 |
| Vanguard Group Inc | 6.24% | 4,088,760 | 6.26M | Sep 29, 2024 |
| Blackrock Inc. | 6.23% | 4,081,038 | 6.24M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Kaufmann Fund | 12.03% | 7,881,000 | 12.06M | Jul 30, 2024 |
| Federated Hermes Kaufmann Small Cap Fund | 11.32% | 7,417,000 | 11.35M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 3.82% | 2,501,083 | 3.83M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.47% | 1,617,996 | 2.48M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.73% | 1,130,792 | 1.73M | Sep 29, 2024 |
| USAA Mutual Fund Tr-Science & Technology Fund | 1.43% | 937,813 | 1.43M | Jul 30, 2024 |